Immunotherapy after radiation shows promise in rare lung cancer
NCT ID NCT02959463
First seen Nov 14, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This early-phase trial tested whether giving the immunotherapy drug pembrolizumab (Keytruda) after radiation therapy is safe for people with malignant pleural mesothelioma, a rare cancer of the lung lining. Twenty-five participants received radiation followed by pembrolizumab. The study focused on side effects and also tracked survival. Results help guide future research but are not yet conclusive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MALIGNANT MESOTHELIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda)
What this could lead to
If successful, this combination could offer a new treatment option for pleural mesothelioma, potentially improving survival.
What could go wrong
This is a very early phase 1 trial with only 25 participants, so results may not apply broadly. The main goal is safety, not yet effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.